https://www.selleckchem.com/pr....oducts/gf109203x.htm
045% lotion demonstrated statistically significant superiority versus vehicle in reducing inflammatory and non-inflammatory lesion counts (least-squares mean percent changes from baseline inflammatory, -57.9% vs -47.8% [P less then 0.001]; noninflam-matory, -56.0% vs -42.0% [P less then 0.001]). Treatment success at week 12 was also greater with tazarotene 0.045% lotion versus vehicle (30.4% vs 17.9%; P less then 0.001). The most frequent treatment-emergent AEs related to tazarotene treatment were application site pain (5.3%), dryness
Like
Comment
Share
